深圳航空已通过公开挂牌方式成功引入深圳市鲲航投资合伙企业(有限合伙)("鲲航投资")作为新投资 者，并于2025年12月18日签署增资协议及相关文件。据此，中国国航及鲲航投资将分别出资约人民币 20.82亿元及人民币20亿元，以认购深圳航空的新增注册资本("第一阶段增资")。于第一阶段增资完成 后，集团所持深圳航空的股权将由49%被摊薄至约28.09%，中国国航及鲲航投资将分别持有深圳航空 51%及约20.91%的股权，深圳航空将继续为公司联营公司。中国国航及鲲航投资将就后续增资适时签署 相关协议，集团所持深圳航空之股权预计将进一步被摊薄。 格隆汇12月18日丨深圳国际(00152.HK)公布，有关公司联营公司深圳航空拟分阶段进行增资扩股，合共 增资人民币160亿元，而集团决定不参与增资。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 承董事會命 深圳國際控股有限公司 聯席公司秘書 劉旺新 2025年12月18日 於本公告日期，董事會的成員包括執行董事李海濤先生、劉征宇先生、王沛航先生 及劉秀麗女士；非執行董事蔡曉平先生；以及獨立非執行董事潘朝金先生、曾志博 士、王國文博士及丁春艷教授。 （於百慕達註冊成立之有限公司） （股份代號：00152） 自願性公告 聯營公司增資擴股之進展 茲提述深圳國際控股有限公司（「本公司」，連同其附屬公司統稱為 「本集團」）日期為 2025 年 8 月 28 日的自願性公告（「該公告」）， 內容有關本公司之聯營公司深圳航空擬分階段進行增資擴股，合共增 資人民幣 160 億元，而本集團決定不參與增資。除非文義另有所指，本 公告所用之詞彙與該公告所界定者具有相同涵義。 本公司僅此宣佈，深圳航空已通過公開掛牌方式成功引入深圳市鯤航 投資合夥企業（有限合夥）（「鯤航投資」）作為新投資者，並於 2025 年 12 ...

Core Insights - The Shenzhen International Energy Storage Technology Exhibition 2026 will take place from August 26 to 28, 2026, at the Shenzhen International Convention and Exhibition Center, focusing on the energy storage industry and its advancements [1][9]. Industry Overview - China, as the world's largest energy producer and consumer, has established a comprehensive clean energy equipment manufacturing industry chain, including hydropower, nuclear power, wind power, and solar energy, leading to unprecedented opportunities for the energy storage sector [1]. - According to the National Energy Administration, by the first half of 2024, the cumulative installed capacity of new energy storage projects in China reached 44.44 million kilowatts (99.06 million kilowatt-hours), representing a growth of over 40% compared to the end of 2023 [1]. Exhibition Details - The exhibition will showcase a wide range of energy storage technologies and materials, energy storage power stations, EPC engineering related facilities, liquid cooling technology, grid dispatch and automation control, and intelligent metering and electricity management systems [2]. - Over 800 leading global suppliers from the energy storage industry are expected to participate, with an exhibition area exceeding 40,000 square meters, making it the largest and most professional international energy storage event in South China [2]. Exhibition Scope - The exhibition will include various sections such as energy storage technology, energy storage systems and solutions, battery technology, battery materials and components, and hydrogen energy and fuel cell industries [6][7]. - Specific areas will feature different types of energy storage batteries, systems, and equipment, including lithium-ion batteries, sodium-sulfur batteries, supercapacitors, and various energy management systems [6][7].

Core Insights - The event "2025 Shenzhen International High-Performance Medical Device Exhibition and Innovative Pharmaceutical Exhibition" was held in Hong Kong, focusing on "Innovative Drugs and Devices, Collaborative Win-Win" [1] - Over 120 companies, universities, and research institutions participated, with more than 300 representatives attending [1] - The exhibition showcased the "hard power" of the Greater Bay Area's pharmaceutical and medical device industry, featuring advanced medical equipment and innovative pharmaceutical achievements [1] Group 1 - The event adopted a "conference + exhibition" model to explore cutting-edge technology trends and collaborative development initiatives [1] - It aimed to deepen cross-border cooperation between Shenzhen and Hong Kong in the pharmaceutical and medical device sectors, contributing to high-quality development in the Greater Bay Area [1] - Notable exhibits included advanced surgical robots and automated models for traditional Chinese medicine, highlighting the industrial vitality of both regions [1] Group 2 - Top experts from institutions like the Chinese Academy of Sciences and the U.S. National Academy of Inventors delivered keynote speeches on topics such as infrared fluorescence imaging and clinical applications of surgical robots [1] - The organizers expressed intentions to further integrate industrial resources and align with international standards to create a closed-loop ecosystem of "research-industry-capital" [1] - This initiative is expected to help the Greater Bay Area establish itself as a world-class hub for the pharmaceutical and medical device industries [1]

Core Insights - The event "2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition Hong Kong Station" focuses on the theme "Innovative Drugs and Devices, Collaborative Win-Win" and aims to deepen cross-border cooperation in the pharmaceutical and medical device sectors between Shenzhen and Hong Kong [1] Group 1: Event Overview - The event is guided by multiple health and regulatory bodies from Shenzhen and Hong Kong, featuring a "conference + exhibition" model to explore cutting-edge technology trends and collaborative development measures [1] - Over 300 representatives from more than 120 enterprises, universities, and research institutions participated, showcasing significant medical devices and innovative pharmaceutical products [4] Group 2: Expert Contributions - Notable experts shared insights on various topics, including the application prospects of infrared fluorescence imaging in precision medicine and global trends in digital healthcare [2] - The discussions highlighted the importance of industry-academia-research collaboration for innovation [2] Group 3: Collaborative Achievements - A series of landmark collaborative achievements were announced, including the launch of the GCOG precision treatment clinical trial and the establishment of a collaborative platform for international clinical trials in the Greater Bay Area [3] - Several partnerships were formed in key areas such as cell gene therapy and drug development, aiming to create a "research-application" integration platform and an international service network [3] Group 4: Innovation Showcase - The event featured high-performance medical devices such as surgical robots and automated immunoassay analyzers, demonstrating the industrial strength and innovative vitality of the Shenzhen-Hong Kong region [4] Group 5: Future Development - The forum focused on themes like cell and gene therapy and opportunities in innovative drug and device development, providing intellectual support for industry growth [5] - The event serves as a model for soft connectivity in the Greater Bay Area's pharmaceutical and medical device industry, promoting a new model of industrial linkage between Shenzhen and Hong Kong [5]

Core Insights - The 32nd Shenzhen International Tea Expo has commenced, showcasing the high-quality development of the Chinese tea industry through various themed events and exhibitions [1][3] - The expo features an exhibition area of 75,000 square meters with 3,700 booths, gathering over 2,000 brand enterprises from home and abroad [3] - The event highlights the vibrant tea consumption market in the Greater Bay Area, with numerous well-known brands participating and engaging in discussions and collaborations [3][7] Group 1 - The expo includes various concurrent events such as the "2025 Chaozhou Kung Fu Tea Conference" and the "World Aged Tea Awards," enhancing the overall experience for attendees [1] - A diverse range of tea products and cultural exchanges are present, attracting thousands of professional buyers and tea enthusiasts [3][7] - The event aims to break traditional exhibition formats by incorporating multi-dimensional content to enhance tea culture experiences [7] Group 2 - The 2025 Shenzhen International Tea Ware Aesthetic Design Exhibition features various themed areas, showcasing both traditional craftsmanship and contemporary design [5] - Notable brands and products, including limited edition items and innovative designs, are highlighted, emphasizing the creativity within the tea ware sector [5] - The international section of the expo has expanded, attracting tea enterprises and cultural institutions from regions such as Hong Kong, Macau, Taiwan, and countries like Malaysia and Japan [7]

Core Viewpoint - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition aims to create an industry exchange platform, focusing on the theme of "Innovative Drugs and Devices, Collaborative Win-Win" to showcase cutting-edge achievements in the pharmaceutical and medical device industries and promote cooperation between Shenzhen and Hong Kong [1] Group 1: Exhibition Overview - The exhibition will take place in Hong Kong on December 11 and in Shenzhen from December 18 to 20, featuring a dual-city model [1] - The Hong Kong segment will focus on international clinical trials, technology and product exports, cell and gene therapy, AI in medical devices, and brain science [1] - The Shenzhen segment will cover the entire pharmaceutical and medical device supply chain, showcasing high-performance medical devices and innovative pharmaceuticals, including biomanufacturing, AI+healthcare, aesthetic devices, and home health [1] Group 2: Participation and Forums - The exhibition will feature over 300 participating companies and institutions, including global leaders like Siemens Healthineers, Medtronic, and Abbott, as well as domestic pioneers [2] - More than 20 high-level sub-forums will be held, addressing key topics such as policy interpretation, cutting-edge technology, clinical practice, market trends, and investment financing [2] - Notable experts and over 2,500 industry leaders will attend the opening ceremony and forums to share insights [2] Group 3: Highlights and Achievements - The exhibition will showcase five major highlights: high standards, broad fields, complete supply chains, new achievements, and a comprehensive ecosystem [3] - Significant technological advancements in Shenzhen's pharmaceutical and medical device sectors will be announced during the opening ceremony [3] - Shenzhen's medical device industry has been integrated into the "20+8" key industrial clusters, with a projected growth in output value from 128 billion to 157.6 billion yuan from 2020 to 2024, maintaining an annual growth rate of 5.3% [3]

Core Viewpoint - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition will take place in two phases, with the Hong Kong station starting on December 11 and the main exhibition in Shenzhen from December 18 to 20, showcasing advancements in the medical device and pharmaceutical industries [1][2]. Group 1: Exhibition Overview - The exhibition adopts a "one exhibition, two cities" model, focusing on the latest achievements from innovation to industrial transformation, and aims to create a platform for industry exchange, resource integration, and trade [2][3]. - The Hong Kong station will emphasize international clinical trials, technology and product exports, and new fields such as AI in medical devices and brain science, while the Shenzhen station will cover the entire pharmaceutical and medical device supply chain [2][3]. Group 2: Industry Development - Shenzhen's pharmaceutical and medical device output is projected to grow from 128 billion yuan in 2020 to 157.6 billion yuan by 2024, with an annual growth rate of 5.3%, maintaining its position as the national leader in medical device output [3]. - The city plans to establish a development framework consisting of "one corridor, two zones, and three bases" to enhance its biopharmaceutical and medical device industries [3]. Group 3: Regional Focus - Pingshan District, as a national biopharmaceutical industry base, has established 13 specialized parks covering over 2.79 million square meters, with a compound annual growth rate of 39.8% in enterprise numbers [4]. - The Guangming District has attracted over 900 medical device companies and is focusing on building a comprehensive ecosystem for biomanufacturing and innovative medical devices [5][6]. Group 4: Exhibition Highlights - The exhibition will feature over 300 participating companies, including international giants like Siemens and Medtronic, and will host more than 20 sub-forums covering key topics such as policy interpretation and cutting-edge technologies [7][8]. - This year's exhibition will continue to emphasize the dual focus on pharmaceuticals and medical devices, showcasing a wide range of innovations and establishing a complete industry chain from research to application [7][8].

Core Points - Shenzhen Airport has successfully launched a direct flight route to Tawau, Malaysia, marking the 60th international passenger route and restoring the airport's international and regional passenger route count to historical peak levels [1] - The airport has opened and enhanced 27 international passenger routes this year, connecting to 60 cities across five continents, with plans to launch a direct flight to Melbourne, Australia [1] - The number of inbound and outbound passengers at Shenzhen Airport has exceeded 6 million in the first 11 months of the year, a 23.4% year-on-year increase, with foreign passenger numbers rising by 44% and visa-free foreign arrivals increasing by 131.8% [1] Industry Developments - With the official operation of the third runway, Shenzhen Airport's annual passenger capacity is expected to reach 80 million, supporting the city's efforts to enhance its global influence and contribute to the construction of a world-class airport cluster in the Guangdong-Hong Kong-Macao Greater Bay Area [2] - The airport aims to improve hardware facilities, optimize personnel inspection processes, implement customs policies, and provide efficient services to elevate its role as an aviation hub and support high-level opening and high-quality development [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： HKD 3,000,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 公司名稱: 深圳國際控股有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00152 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | ...